D. Craig Allred, M.D. - Publications

Publications, Books/Chapters, Reviews/Commentaries, Editorials

Selected journal publications:

Lampkin SR, Allred DC: Preparation of paraffin blocks and sections containing multiple tissue samples using a skin biopsy punch. J Histotechnol 13:121-123, 1990.

Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL: HER-2/neu in node-negative breast cancer. Prognostic significance of overexpression influenced by presence of in-situ carcinoma. J Clin Oncol 10:599-605, 1992. [PDF]

Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL: HER-2/neu in node-negative breast cancer: Incidence of overexpression and its relationship to other prognostic factors changes during the progression of tumors. Human Pathol 23:974-979, 1992. (Topic of editorial)

Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, McGuire WL: Accumulation of mutant p53 is associated with increased proliferation and poor clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993. (Topic of editorial; Third most cited paper in breast cancer during decade of 1990-2000) [Abstract]

Allred DC, Clark GM, Tandon AK, McGuire WL: Immunohistochemistry on histological sections made from small (50 mg) samples of pulverized breast cancer. J Histotechnol 16:117-120, 1993.

Elledge RM, Clark GM, Fuqua SAW, Yu YY, Allred DC: p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54:3752-3757, 1994. [Abstract]

Albain KS, Clark GM, Allred DC: Breast cancer outcome and predictors of outcome: are there age differentials. A review, plus new analysis of the San Antonio early breast cancer data base. J Natl Cancer Inst Mongr 16:35-42, 1994.

O'Connell P, Pekkel V, Fuqua SAW, Osborne CK, Allred DC: Molecular genetic studies of early breast cancer evolution by LOH. Breast Cancer Res Treat 32:5-12, 1994.

Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, Tormey DC, Allred DC: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87:1254-1256, 1995.

Chen Y, Chen CF, Riley DJ, Allred DC, Chen PL, Von Hoff D, Osborne CK, Lee WH: Aberrant subcellular localization of BRCA1 in breast cancer. Science 270:789-791, 1995. [Abstract]

Elledge RM, Lock-Lim S, Allred DC, Hilsenbeck SG, Cordner L: p53 mutation and tamoxifen resistance in breast cancer. Clin Cancer Res 1:1203-12-8, 1995. [Abstract]

Brown RW, Allred DC, Clark GM, Osborne CK, Hilsenbeck SG: Prognostic value of Ki67 compared to S phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2:585-592, 1996 [Abstract]

Makris A, Allred DC, Powles TJ, Dowsett M, Fernando IN, Trott PA, Ashley S, Ormerod MG, Titley JC, Osborne CK: Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 44:65-74, 1997. [PDF]

Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3:593-600, 1997. [Abstract]

Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Puch R, Ciocca D, Ravdin P, O’Sullivan J, Rivkin S. Martino, S, Osborne CK. Bcl-2, p53, and response to tamoxifen in ER-positive metastatic breast cancer: a Southwest Oncology Group Study. J Clin Oncol 15:1916-1922, 1997. [PDF]

Clark GM, Allred DC, Hilsenbeck SG, Osborne CK, Lee WH: Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res 57:5505-5508, 1997. (annotated in: Breast Diseases. A Year Book Quarterly 9(3):270-271, 1998) [Abstract]

Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 48:11-20, 1998. [PDF]

Berardo M, de Moor C, Elledge RM, Osborne CK, Allred DC: Bcl-2 and apoptosis in node-positive breast cancer. Cancer 82:1296-1302, 1998. (annotated in Breast Diseases: A Year Book Quarterly, Mosby-Year Book, Inc., December, 1998) [PDF]

O'Connell P, Pekkel V, Fuqua SAW, Osborne CK, Allred DC: Loss-of-heterozygosity analysis in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90:697-703, 1998. [PDF]

Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred DC, Norton L, Liu ET: erbB-2 and p53 modulate the efficacy of adjuvant therapy in node positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998. [PDF]

Elledge RM, Green S, Ciocca D, Allred DC, Clark GM, Hill J, Ravdin P, O’Sullivan J, Martino S, Osborne CK: HER-2 expression and response to tamoxifen in ER-positive breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 4:7-12, 1998. [Abstract]

Breast Cancer Progress Review Group (DC Allred; member and co-author): Charting the Course: Priorities for Breast Cancer Research. Report for the National Cancer Institute. August, 1999. [PDF]

Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC, Dowsett M: Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study. Breast Cancer Res Treat 53:51-59, 1999. [PDF]

Harvey JM, Clark GM, Hilsenbeck SG, Osborne CKO, Allred DC: Immunohistochemistry is superior to ligand binding assay for evaluating estrogen receptor status in a study of 1,982 breast cancer patients. J Clin Oncol 17:1474-1481, 1999. [PDF]

O’Connell, P, Fischbach K, Hilsenbeck SG, Mohsin K, Fuqua SAW, Clark GM, Osborne CK, Allred DC: Loss-of-heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst 91:1391-1397. 1999. [PDF]

Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM: Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 17:1442-1448, 1999. [PDF]

Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne, CK, Dowsett M. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17:3058-3063, 1999. [PDF]

Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK, Osborne CK, Dowsett M: Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res 6:616-621, 2000 [PDF]

Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK: ER and PgR by ligand binding assay compared with ER, PgR, and pS2 by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 89:111-117, 2000. [PDF]

Fuqua SAW, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O’Connell P, Allred DC. A hypersensitive estrogen receptor mutation in premalignant breast lesions. Cancer Res 60:4026-4029, 2000. (Abstracted in Science 289:1259, 2000) [PDF]

Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89:2145-2152, 2000. [PDF]

Page DL, Gray R, Allred DC, Dressler LG, Hatfield AK, Martino S, Robert NJ, Wood WC. Prediction of node negative breast cancer outcome by histoligic grading and S-phase analysis by flow cytometry: an ECOG study (2192). Am J Clin Oncol 24(1):10-18, 2001. [PDF]

Martin M.D., Fishback K, Osborne CK, Mohsin SK, Allred DC, O’Connell P: LOH events including the MTA1 gene impede breast cancer metastasis. Cancer Res 61:3578-3580, 2001. [PDF]

Institute of Medicine/National Research Council (DC Allred; committee member and co-author): Mammography and Beyond. Developing Technologies for the Early Detection of Breast Cancer. National Academy Press. Washington DC, 2001. [Link to PDF]

Love RR, Duc NB, Dinh NV, Dinh NV, Shen T-Z, Havighurst TC, Allred DC, DeMets DL: Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. J Natl Cancer Inst 94(9), 662-669, 2002. [PDF]

Love RR, Ba NB, Allred DC, Binh NC, Dinh NV, Kha NN, Thuan TV, Mohsin SK, Roanh LD, Khang HX, Tran TL, Quy TT, Thuy NV, The PN, Cau TT, Tung ND, Huong DT, Quang LM, Hien NN, Thuong L, Shen TZ, Xin Y, Zhang Q, Havighurst TC, Yang YF, Hillner BE, DeMets DL: Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 20:2559-2566, 2002. (Topic of editorial) [PDF]

Medina D, Kittrell FS, Shepard A, Stephens LC, Jiang C, Lu J, Allred DC, McCarthy M, Ullrich RL: Biological and genetic properties of the p53 null preneoplastic mammary epithelium.
The FASEB Journal 16:881-883, 2002. [PDF]

Wang J, Buchholtz T, Middleton LP, Allred DC, Tucker SL, Kuerer HM, Esteva FJ, Hortobagyi GN, Sahin AA: Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Cancer 94:3107-3114, 2002 [PDF]

American Cancer Society and American Joint Committee on Cancer (DC Allred; committee member of Breast Task Force): AJCC Cancer Staging Handbook. Sixth Edition. Springer-Verlag, New York, Berlin, Heidelberg, 2002.

Singletary SE, Allred DC, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RVP, Morrow M. Page DL, Recht A, Theriault RL, Thor An, Weaver DL, Weiand S, Greene FL: Staging System for Breast Cancer: Revision of the 6th Edition of the American Joint Committee on Cancer Staging Manual. J Clin Oncol 20:3628-3636, 2002; and Surgical Clinics of North America 83(4), 803-819, 2003.

Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM: Survival of patients with metastatic breast cancer: importance of prognostic markers of the primary tumor. Cancer 97:545-553, 2003 [PDF]

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, Wong J, Schiff R, Allred DC, Clark GM, Schiff R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361, 2003. (see accompanying editorial J Natl Cancer Inst 95:338-340) [PDF]

Mohsin SK, Zhang M, Clark GM, Allred DC: Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 199:432-435, 2003. [PDF]

Love RL, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL, Allred DC: HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21:453-457, 2003. [PDF]

Lee AV, Zhang P, Ivanova M, Bonnette S, Osterreich S, Rosen JM, Grimm S, Hovey RC, Vonderhaar BK, Kahn CR, Torres D, George J, Moshin S, Allred DC, Hadsell DL: Developmental and hormonal signals dramatically alter the localization and abundance of insulin receptor substrate proteins in the mammary gland. Endocrinology 144:2683-2694, 2003. [PDF]

Fuqua SAW, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC: Estrogen receptor protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63:2434-2439, 2003. [PDF]

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Guiterrez MG, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O’Connell P: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369, 2003. (Topic of Commentary/Editorial) [PDF]

Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Guiterrez MC, Lucci A Jr, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC: Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4(5):348-53, 2003.[Abstract]

Arpino G, Allred DC, Mohsin SK, Weiss HL, Conrow D, Elledge RM: Lobular neoplasia on core needle biopsy – clinical significance. Cancer 101:242-250, 2004. [PDF]

Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horowitz KB, Fuqua SAW: Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10:2751-2760, 2004. [PDF]

Mohsin SK, Clark GM, Havighurst T, Weiss H, Berardo M, Roanh LD, To TV, Zhang Q, Love RR, Allred DC. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Modern Pathol 17(12):1545-1554, 2004. [PDF]

Arpino G, Green S, Allred DC, Ravdin P, Lew D, Martino S, Osborne CK, Elledge RM: HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer: a Southwest Oncology Group study. Clin Cancer Res 10:5670-5676, 2004. [PDF]

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23(6):1169-1177, 2005. [PDF]

Nichols HB, Trentham-Dietz A, Love RR, Hampton JM, Hoang Anh PT, Allred DC, Mohsin SK, Newcomb PA: Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev 14(1): 41-47, 2005. [PDF]

Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC: Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23:2460-2468, 2005. [PDF]

Mohsin SK, O’Connell P, Allred DC, Libby AL: Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat 90:249-256, 2005. [PDF]

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M.Molecular changes in tamoxifen-resistance breast cancer: relationship between estrogen receptor, HER-2 and p38 mitogen-activated protein kinase. J Clin Oncol 23(11):2469-2476, 2005. [PDF]

Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L, Leuzzi M, Gago F, Elledge R, Mohsin SK: Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 92:69-75, 2005. [PDF]

Tham YL, Gomez LF, Mohsin S, Gutierrez MC, Weiss H, Hilsenbeck SG, Elledge RM, Chamness GC, Osborne CK, Allred DC, Chang JC: Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat 94:279-284, 2005. [PDF]

Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK: Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclopohosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup protocol INT-0102. J Clin Oncol 23:8313-8321, 2005. [PDF]

Mohsin SK, Allred DC, Osborne CK, Cruz A, Otto P, Chew H, Clark GM, Elledge RM: Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer. Breast Cancer Res Treat 94:205-211, 2005. [PDF]

Harvell DME, Sartorius CA, Richer JK, Allred DC, Horowitz KB. Estradiol regulates different genes in breast cancer cell lines and tumors and imprints a subset of genes in tumors. Endocrinology 147:700-713, 2006. [PDF]

Martin M.D., Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC, O’Connell P: Breast tumors that overexpress nuclear metastasis-associated (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 95:7-12, 2006. [PDF]

Lee S, Mohsin SK, Hilsenbeck SG, Medina D, Allred DC: Hormone receptors and growth in hyperplastic enlarged lobular units (HELUs) – an early precursor of breast cancer. Breast Cancer Res. 8:R6, 2006. [PDF]

Ma X-J, Hilsenbeck SG, Wang W, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MG: The HOXB13:IL17BR expression index is a prognostic factor in early stage breast cancer. Submitted to J Clin Oncol 03/20/06.
Publications, Books/Chapters, Reviews/Commentaries, Editorials

Books/Chapters:

Allred DC, Elledge R, Clark GM, Fuqua SAW: The p53 tumor suppressor gene in human breast cancer. In: Mammary Tumorigenesis and Malignant Progression. Eds. RB Dickson and ME Lippman. Kluwer Academic Publishers, 1994, pp 63-77.

Elledge RM, Allred DC. p53 status: impact on breast tumour biology and response to therapy. In: Prognostic and Predictive Value of p53. Scientific Updates, 1. Ed. JGM Klijn. Elsevier Science BV, 1997, pp 63-76.

Allred DC, Mohsin S: Biology features of human premalignant breast disease. In: Diseases of the Breast. Second Edition. Eds. Harris JR, Lippman ME, Morrow M, Hellman S, Osborne CK. Lippincott Williams and Wilkins, 1999, pp 355-366.

Brown P, Fuqua SAW, Allred DC: Estrogen receptor in the pathogenesis of breast cancer. In: Contemporary Endocrinology: Endocrine Oncology. Ed. SP Ethier. Humana Press, Totowa, NJ, 2000, pp 49-68.

Allred DC: Biological characteristics of ductal carcinoma in situ. In: Ductal Carcinoma In Situ of the Breast. 2nd Edition. Ed. ML Silverstein. Lipincott, Williams and Wilkins, 2002, pp37-48.

Mohsin SK, Bardou VJ, Arpino G, Chamness GC, Allred DC: Prognostic and predictive factors in breast cancer: an evidence-based medicine approach. In: Breast Cancer Management. Ed. K Tonkin, DM Reese, MS Aapro, AU Buzdar. Lippincott Williams and Wilkins, 2003, pp 391-410.

Allred DC, Hilsenbeck SG, Mohsin SK: Biological features of human premalignant breast disease. In: Diseases of the Breast, 3rd Editon. Ed. Harris JR, Lippman ME, Morrow M, Hellman S, Osborne CK. Lippincott Williams and Wilkins (in press)
Publications, Books/Chapters, Reviews/Commentaries, Editorials

Reviews/Commentaries:

Bookstein R, Allred DC: Recessive oncogenes. Cancer 71:1179-1186, 1993.

Elledge RM, Fuqua SAW, Clark GC, Pujol P, Allred DC: The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treat 27:95-102, 1993.

Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 32:39-47, 1994.

Allred DC, Harvey JM, Berardo M, Clark GM : Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathol 11(2):155-168, 1998.

Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treatment 52:79-98, 1998.

Mohsin, SK, Allred DC: Immunohistochemical biomarkers in breast cancer. J Histotechnol 22:249-261, 1999.

Fitzgibbons PL, Page DL, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ: Prognostic factors in breast cancer: College of American Pathology consensus statement 1999. Arch Pathol Lab Med 124:966-978, 2000.

Allred DC, Mohsin SK: Biological features of premalignant disease in the human breast. J Mammary Gland Biol Neoplasia. 5(4):351-364, 2000.

Allred DC, Mohsin SK, Fuqua SAW: Histological and biological evolution of human premalignant breast disease. Endocrine-Related Cancer 8:47-61, 2001.
Publications, Books/Chapters, Reviews/Commentaries, Editorials

Editorials:

Hilsenbeck SG, Allred DC: Improved methods of estimating mitotic activity in solid tumors. Human Pathol 23:601-602, 1992.

Allred DC: Should immunohistochemistry examination replace biochemical hormone receptor assays in breast cancerAm J Clin Pathol 99:1-3, 1993.

Allred DC, Hilsenbeck SG: Biomarkers in benign breast disease and breast cancer risk. J Natl Cancer Inst 90:1247-1248, 1998.

Allred DC: Prognostic and predictive factors in breast cancer by immunohistochemistry. Breast Diseases: A Year Book Quarterly 10:144-146, 1999.

Allred DC, Elledge RM: Caution regarding micrometastatic breast cancer in sentinel lymph nodes. Cancer 86:905-907, 1999.

Allred DC, Swanson PE: Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 113:171-175, 2000.
Publications, Books/Chapters, Reviews/Commentaries, Editorials